SecBot SecBot
8-K ·Filed Feb 24, 2026

CYTK

CYTOKINETICS INC
MIXED
Impact 7/10
Horizonmonths Processed8mo ago SEC0001193125-26-067012
8-K Item 2.02: Earnings release
Actionable Insight ◆ Mixed

Monitor early U.S. commercial uptake of MYQORZO and topline results from the ACACIA-HCM trial in Q2 2026, which could validate expansion into non-obstructive HCM. The high cash balance supports operations, but the significant increase in operating expenses raises questions about profitability timeline.

DirectionMixed
Confidencehigh
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$62.89
T+0 close · Feb 24, 2026 · via day close
Latest settled
+25.25%
T+60 · $78.77
Vs SPY
+18.30%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Feb 25 $62.89entry
  2. T+1 · 9mo ago −0.41%α +0.13% · $62.63
  3. T+5 · 9mo ago −0.99%α +0.11% · $62.27
  4. T+20 · 8mo ago −0.80%α +4.44% · $62.39
  5. T+60 · 6mo ago +25.25%α +18.30% · $78.77
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Cytokinetics reported its transition to a commercial-stage company following FDA, China, and EU approvals of MYQORZO for obstructive HCM, with the U.S. launch underway. The company posted a wider net loss of $785M in 2025 due to increased R&D and commercial readiness spending, while maintaining ~$1.22B in cash. It provided 2026 guidance with $830M–$870M in combined R&D and SG&A expenses.

Key Financial Metrics

Revenue
$88.0M
+376.3% YoY
EPS
$-6.54

Key Facts

  • MYQORZO approved in U.S., China, and EU for symptomatic obstructive HCM; U.S. launch began in January 2026 with first prescriptions dispensed.
  • Total 2025 revenue was $88.0M (up from $18.5M in 2024), driven by a $52.4M technology transfer payment to Bayer and $15.0M in milestone revenue from MYQORZO approvals.
  • 2025 net loss was $785.0M (vs. $589.5M in 2024); Q4 2025 net loss was $183.0M (vs. $150.0M in Q4 2024), reflecting higher R&D and G&A expenses for commercialization.
  • Cash, cash equivalents, and investments were $1.22B as of December 31, 2025, down from $1.25B in Q3; excluding a $100M loan draw, cash declined by $134M in Q4.
  • 2026 guidance: GAAP combined R&D and SG&A expenses of $830M–$870M, including $120M–$130M in non-cash stock-based compensation.

Financial Impact

Revenue increased 376% YoY to $88.0M in 2025, but net loss widened by $195.5M due to $76.6M higher R&D and $69.0M higher G&A expenses. Cash burn (excluding financing) was $134M in Q4 2025.

revenuenet lossepscashr&dsg&a

Segment Breakdown

SegmentRevenue
aficamten$15.0M
technology transfer$52.4M

Risk Factors

  • High cash burn rate ($134M in Q4 excluding financing) could pressure the balance sheet if product revenue does not scale quickly.
  • Future profitability depends on MYQORZO's commercial success and additional regulatory approvals, which are not guaranteed.
  • Increased G&A spend ($284.3M in 2025) reflects sales force buildout, creating fixed costs that require strong revenue growth to offset.

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-067012
Document: cytk-20260224.htm0001193125-26-067012
Document: 0001193125-26-067012-index-headers.html0001193125-26-067012
Document: 0001193125-26-067012-index.html0001193125-26-067012
Document: 0001193125-26-067012.txt0001193125-26-067012
CONTEXT: Previous Earnings (2026-02-24)0001193125-26-067012

Track record

46 reports on CYTK

Performance horizon

7 of 11 bullish or bearish reports moved the stock their way by T+20. Best: +8.59% at T+20 after the Sep 15, 2026 report. 10 of 11 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $53.76 Now $53.17 −1.10% settles Dec 15
  2. Nov 12, 20264d ago Insider Cluster Neutral 3/10 Entry $56.13 Now $53.17 −5.27% settles Dec 14
  3. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $56.18 Now $53.17 −5.36% settles Dec 9
  4. Nov 9, 20267d ago 144 Neutral 2/10 Entry $56.18 Now $53.17 −5.36% settles Dec 9
  5. Nov 9, 20267d ago Institutional Cluster Neutral 3/10 Entry $55.14 Now $53.17 −3.57% settles Dec 8
  6. Nov 9, 20267d ago Press Release Neutral 4/10 Entry $55.14 Now $53.17 −3.57% settles Dec 8
  7. Nov 4, 202612d ago 8-K Bullish 6/10 No price data
  8. Nov 4, 202612d ago Press Release Neutral 5/10 Entry $55.55 Now $53.17 −4.28% settles Dec 4
  9. Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $63.60 Now $53.17 −16.40% settles Dec 3
  10. Nov 2, 202614d ago Press Release Neutral 3/10 Entry $62.03 Now $53.17 −14.28% settles Dec 1
Showing 10 of 46

US Market Status

Market Closed · Opens in 9h 14m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Feb 24, 2026